scholarly journals Differences in Adverse Event Reporting Rates of Therapeutic Failure Between Two Once-daily Extended-release Methylphenidate Medications in Canada: Analysis of Spontaneous Adverse Event Reporting Databases

2017 ◽  
Vol 39 (10) ◽  
pp. 2006-2023 ◽  
Author(s):  
Laura Park-Wyllie ◽  
Judy van Stralen ◽  
Genaro Castillon ◽  
Stephen E. Sherman ◽  
Doron Almagor
Keyword(s):  
Adverse Event ◽  
Extended Release ◽  
Adverse Event Reporting ◽  
Therapeutic Failure ◽  
Event Reporting ◽  
Once Daily ◽  
Reporting Rates ◽  
Spontaneous Adverse Event

scholarly journals Adverse event reporting in the recent study by Imanaka et al. describing the efficacy and safety of tapentadol extended release for tumor-related pain

2014 ◽  
Vol 30 (9) ◽  
pp. 1909-1910 ◽  
Author(s):  
Keiichiro Imanaka ◽  
Yushin Tominaga ◽  
Mila Etropolski ◽  
Ilse Van Hove ◽  
Masaki Ohsaka ◽  
...  
Keyword(s):  
Adverse Event ◽  
Extended Release ◽  
Adverse Event Reporting ◽  
Efficacy And Safety ◽  
Event Reporting

Patterns in spontaneous adverse event reporting among branded and generic antiepileptic drugs

2015 ◽  
Vol 97 (5) ◽  
pp. 508-517 ◽  
Author(s):  
J Bohn ◽  
C Kortepeter ◽  
M Muñoz ◽  
K Simms ◽  
S Montenegro ◽  
...  
Keyword(s):  
Adverse Event ◽  
Antiepileptic Drugs ◽  
Adverse Event Reporting ◽  
Event Reporting ◽  
Spontaneous Adverse Event

Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine

Neurology ◽  
2019 ◽  
Vol 92 (21) ◽  
pp. e2401-e2405 ◽  
Author(s):  
Tiffany Kim ◽  
Corrinne G. Kulick ◽  
Cindy M. Kortepeter ◽  
Allen Brinker ◽  
Peter Waldron
Keyword(s):  
Adverse Event ◽  
Hemophagocytic Lymphohistiocytosis ◽  
Adverse Reactions ◽  
Adverse Event Reporting System ◽  
Adverse Event Reporting ◽  
Case Definition ◽  
Drug Discontinuation ◽  
Once Daily ◽  
Definition Of ◽  
Spontaneous Adverse Event

ObjectiveTo describe adverse event reports of hemophagocytic lymphohistiocytosis (HLH) reported in association with lamotrigine.MethodsThe Food and Drug Administration Adverse Event Reporting System database of spontaneous adverse event reports and medical literature databases were searched for cases of HLH reported in association with lamotrigine. Cases were included if they met the case definition of suspected or confirmed HLH and if causal association was assessed as robust or supportive.ResultsEight cases met the case definition for HLH and were deemed causally associated with lamotrigine. These 8 cases of HLH had a plausible temporal relationship because they occurred within a 24-day interval from lamotrigine initiation. The doses ranged from 25 mg every other day to 250 mg once daily in the 6 cases that reported this information. Seven patients improved with drug discontinuation and one patient died after drug discontinuation and receiving an unspecified chemotherapy.ConclusionsLamotrigine is associated with immune-related adverse reactions including HLH. HLH is a potentially fatal event; prompt recognition and early therapeutic intervention to mitigate the event is important in improving patient outcomes.

Sign in / Sign up

Export Citation Format

Share Document